NAD+ dosage: amounts and trial duration
A study amount makes sense beside the ingredient, the participants and the length of the experiment. Remove those details and the number becomes far too easy to misuse.
Oral trial amounts
The table records what researchers administered. Each row is an experiment with its own question; none selects treatment for an individual.
| Study and participants | What participants received |
|---|---|
| Conze: healthy overweight adults | NR, 100, 300 or 1000 mg/day for 8 weeks |
| Martens: healthy middle-aged and older adults | NR, 1000 mg/day for 6 weeks |
| Irie: healthy men | NMN, a single 100, 250 or 500 mg amount |
| Yoshino: prediabetic, postmenopausal women | NMN, 250 mg/day for 10 weeks |
| Yi: healthy middle-aged adults | NMN, 300, 600 or 900 mg/day for 60 days |
The 2025 review also covers NR research extending to 3000 mg/day. Different populations and short observation periods limit what such safety experiments can establish. An NR maximum tells me how far a safety experiment went.
The word “optimal”
The multicenter NMN paper identified 600 mg/day as optimal within its trial. All NMN groups had higher blood NAD+, and walking distance improved. The authors' selection does not demonstrate that this amount was best for every outcome, every participant or people outside the experiment.
The particulars of that trial carry more authority for me than its choice of adjective. The same amount could answer a blood-biomarker question while leaving a functional question unresolved. Personal dose selection requires a medical assessment that this website cannot provide.
One administration and repeated use
After a single 1000 mg administration of NR, blood NAD+ rose over the following 24 hours. The eight-week NR experiment instead tracked a sustained rise during repeated administration. These are different observations about time.
The published work does not establish a universal onset of benefit. A blood concentration can rise before any useful functional effect has been demonstrated. That distinction matters particularly when a question about energy gets answered with the time of a blood draw.
The infusion unit
The NAD+ infusion pilot administered 3 micromoles per minute for 6 hours. A micromole expresses a quantity of molecules; the rate describes how much entered the infusion each minute. This is the protocol reported in that study.
Nearly all infused NAD+ was removed from plasma during roughly the first two hours. That observation concerns processing during an ongoing infusion, and cannot be converted into an effective treatment amount or a schedule for shots. The IV NAD+ page examines the clearance finding in its own setting.
Product condition
NAD+ and NMN absorb moisture and can degrade with heat or damp. Heat and light can also damage prepared injectable NAD+. Purity and actual content vary among supplement products, and outside testing cannot be assumed for every bottle.
An experiment tests the material supplied to that experiment. I cannot extend its quality checks to something else carrying the same ingredient name. The contamination concern for compounded injections has an additional, documented history in the recall discussion.